2Amieva, H., et al. (2008) Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Annals of Neurology, 64(5), 492-498.
3 Small S, A., (2001) Age-related memory decline: current concepts and future directions. Archives of Neurology, 58(3), 360-4. [abstract]
4 Celsis, P. (2000) Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer’s disease? Annals of Medicine, 32(1), 6-14.
5 Small G, W. (2002) What we need to know about age related memory loss. British Medical Journal, 22;324(7352), 1502-5.
6Blendon, R, J. et al. (2011) Key Findings from a Five-Country Survey of Public Attitudes about Alzheimer’s Disease. Poster presented at AAIC, July 2011 in Harvard press release http://www.hsph.harvard.edu/news/press-releases/2011-releases/alzheimers-international-survey.html (retrieved August 2011)
7Ferri, C., et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet, 17; 366(9503), 2112-2117.
8Carrillo, M, C., et al. (2009) Early risk assessment for Alzheimer’s disease. Alzheimer’s & Dementia, 5, 182-196.
9Ballard, C., et al. (2011) Alzheimer’s disease. Lancet,377, 1019 – 1031.
10Van Den Heuvel, C., et al. (2007) Traumatic brain injury and Alzheimer’s disease: a review. Progress in Brain Research, 161, 303-316.
11Ronald, C., et al. (1999) MD mild cognitive impairment: clinical characterization and outcome. Archives of Neurology, 56, 303-308. http://archneur.ama-assn.org/cgi/content/full/56/3/303 (retrieved August 2011)
12Lonie, J, A. (2009). Dual task performance in early Alzheimer’s disease, amnestic mild cognitive impairment and depression. Psychological Medicine. 39, 23–31.
13 Alzheimer’s Disease Facts and Figures, Special Report: Mild Cognitive Impairment and Early-Stage Alzheimer’s Disease (2009)
14Matthews, F, E. (2008) Two-year progression from mild cognitive impairment to dementia: To what extent do different definitions degree? Journal of the American Geriatrics Society, 56(8), 1424-1433.
15Wimo, A., et al. (2003) The magnitude of dementia occurrence in the world. Alzheimer’s Disease and Associated Disorders, 17(2), 63-67.
16Brookmeyer, R., et al. (1998) Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health, 88, 1337–1342.
17Carillo, M, C., et al. Early Risk Assessment for Alzheimer’s disease. Alzheimer’s & Dementia, 5, 182-196.
18Dubois, B., et al. (2004) Amnesiac MCI or prodromal AD? The Lancet Neurology, 3, 246-248.
19 http://alzheimers.org.uk/site/scripts/documents_info.php?documentID=120 (retrieved August 2011)
20Amieva, H. (2008) Prodromal Alzheimer’s disease: Successive emergence of the clinical symptoms. Annals of Neurology, 64, 492– 498.
21http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=260 (retrieved August 2011)
22Cedazo-Minguez, A., et al. (2010) Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects. Experimental Gerontology, 45, 5-14.
23Morris, J, C., et al. Mild cognitive impairment represents early stage Alzheimer disease. Archives of Neurology, 58(3), 397-405.
24DeKosky, S, T., et al. (2003) Looking backward to move forward: early detection of neurodegenerative disorders. Science, 302(5646), 830-834.
25Khachaturian, Z, S. (2005) Diagnosis of Alzheimer’s disease: two decades of progress. Alzheimer’s & Dementia, 93-98.
26Tondelli, M., et al. (2011) Structural MRI changes detectable up to 10 years before clinical Alzheimer’s disease. Neurobiology of Aging.
27Mattsson, N., et al. (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Journal of the American Medical Association, 302, 385–393.
28Herholz, K., et al. (2011) Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurology, 10, 667-670.
29Rabinovici, G, D., et al. (2007) 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology, 68, 1205–1218.
30Small, G, W., et al. (2008) Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurology, 7, 161-172.
31Hua, X., et al. (2008) Tensor-based morphometry as a neuroimaging biomarker for Alzheimer’s disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage, 43, 458–69.
32 http://alzheimers.org.uk/site/scripts/documents_info.php?documentID=121 (retrieved August 2011)
33 http://alzheimers.org.uk/site/scripts/documents_info.php?documentID=753&pageNumber=4 (retrieved August 2011)
34Biomarkers Definitions Working Group. (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69, 89–95 in Cummings, J, L. (2011) Biomarkers in Alzheimer’s disease drug development. Alzheimer’s & Dementia, 7, e13-e44.
35Cummings, J, L. (2011) Biomarkers in Alzheimer’s disease drug development. Alzheimer’s & Dementia, 7, e13-e44.
36Shaw, L, M., et al. (2008) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nature Reviews Drug Discovery, 6, 295–303.
37Hansson, O., et al. (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology, 5, 228–234.
38Klunk, W, E., et al. (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Annals of Neurology, 55, 306–319.
39US National Institutes of Health, National Institute on Aging http://www.nia.nih.gov/NewsAndEvents/PressReleases/PR20110419guidelines.htm